Proteomics

Dataset Information

0

FDA-approved Disulfiram Inhibits the NLRP3 Inflammasome


ABSTRACT: The NLRP3 inflammasome is dysregulated in autoinflammatory disorders caused by inherited mutations and contributes to the pathogenesis of several chronic inflammatory diseases. In this study, we discovered that disulfiram, a safe FDA-approved drug, specifically inhibits the NLRP3 inflammasome, but not the NLRC4 or AIM2 inflammasomes. Disulfiram suppresses caspase-1 activation, ASC speck formation, and pyroptosis induced by several stimuli that activate NLRP3. Mechanistically, NLRP3 is palmitoylated at cysteine 126, a modification required for its localization to the trans-Golgi network and inflammasome activation which was inhibited by disulfiram. Administration of disulfiram to animals inhibited the NLRP3, but not the NLRC4 inflammasome in vivo. Our study uncovers a mechanism by which disulfiram targets NLRP3 and provides a rationale for using a safe FDA-approved drug for the treatment of NLRP3-associated inflammatory diseases.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Cell Culture

SUBMITTER: Jie Xu  

LAB HEAD: Jie Xu

PROVIDER: PXD054126 | Pride | 2024-07-25

REPOSITORIES: Pride

Dataset's files

Source:

Similar Datasets

2024-04-23 | PXD051489 | Pride
2023-11-25 | PXD041763 | Pride
2018-04-27 | GSE110452 | GEO
2014-09-08 | E-GEOD-57253 | biostudies-arrayexpress
2025-02-09 | GSE283939 | GEO
2022-06-09 | PXD016019 | Pride
2022-11-17 | PXD035302 | Pride
2026-06-04 | PXD068076 | Pride
2014-09-08 | GSE57253 | GEO
2024-08-14 | PXD047745 | Pride